Loading
A phase 2/3 trial testing SPH4336 in HR-positive / HER2-negative breast cancer, now recruiting.
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer is a phase 2/3 interventional study registered as NCT05744687, led by Shanghai Pharmaceuticals, and recruiting on the registry. Official title: Randomised, Double-blind, Placebo-controlled, Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer. Planned enrolment is 374 participants (estimated). The study started in 2023-04-24 and primary completion is expected in 2026-05-31. No results have been posted on ClinicalTrials.gov.